×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
XLO – xilio therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
XLO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/2
03:47 pm
xlo
Xilio Therapeutics (NASDAQ:XLO) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Xilio Therapeutics (NASDAQ:XLO) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
11/26
02:24 pm
xlo
Xilio Therapeutics (NASDAQ:XLO) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Xilio Therapeutics (NASDAQ:XLO) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
11/13
07:30 am
xlo
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results
Medium
Report
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results
11/11
04:06 am
xlo
Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript [Seeking Alpha]
Medium
Report
Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript [Seeking Alpha]
11/7
09:05 am
xlo
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
High
Report
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
11/7
09:01 am
xlo
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
Medium
Report
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
11/3
04:30 pm
xlo
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/30
09:35 am
xlo
Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting [Yahoo! Finance]
Medium
Report
Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/1
04:37 pm
xlo
Form 4 Xilio Therapeutics, Inc. For: Nov 26 Filed by: GILEAD SCIENCES, INC.
Medium
Report
Form 4 Xilio Therapeutics, Inc. For: Nov 26 Filed by: GILEAD SCIENCES, INC.
11/25
04:17 pm
xlo
Form S-8 Xilio Therapeutics, Inc.
Low
Report
Form S-8 Xilio Therapeutics, Inc.
11/25
04:10 pm
xlo
Form 4 Xilio Therapeutics, Inc. For: Nov 21 Filed by: Brennan Kevin M.
Low
Report
Form 4 Xilio Therapeutics, Inc. For: Nov 21 Filed by: Brennan Kevin M.
11/25
04:10 pm
xlo
Form 4 Xilio Therapeutics, Inc. For: Nov 21 Filed by: Russo Rene
Low
Report
Form 4 Xilio Therapeutics, Inc. For: Nov 21 Filed by: Russo Rene
11/25
04:10 pm
xlo
Form 4 Xilio Therapeutics, Inc. For: Nov 21 Filed by: Luptakova Katarina
Low
Report
Form 4 Xilio Therapeutics, Inc. For: Nov 21 Filed by: Luptakova Katarina
11/25
04:10 pm
xlo
Form 4 Xilio Therapeutics, Inc. For: Nov 21 Filed by: Frankenfield Christopher James
Low
Report
Form 4 Xilio Therapeutics, Inc. For: Nov 21 Filed by: Frankenfield Christopher James
11/25
04:05 pm
xlo
Form 8-K Xilio Therapeutics, Inc. For: Nov 21
Low
Report
Form 8-K Xilio Therapeutics, Inc. For: Nov 21
11/14
04:04 pm
xlo
Form SCHEDULE 13G/A Xilio Therapeutics, Inc. Filed by: Point72 Asset Management, L.P.
Low
Report
Form SCHEDULE 13G/A Xilio Therapeutics, Inc. Filed by: Point72 Asset Management, L.P.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: